Real-World Hemoglobin A1c Changes, Prescribing Provider Types, and Medication Dose Among Patients with Type 2 Diabetes Mellitus Initiating Treatment with Oral Semaglutide

INTRODUCTION: Given the lack of real-world data on oral semaglutide use outside clinical trials, the purpose of this study was to describe dose, prescriber specialty, and change in hemoglobin A1c (HbA1c) after 6 months of oral semaglutide treatment for patients with type 2 diabetes mellitus (T2DM)....

Descripción completa

Detalles Bibliográficos
Autores principales: Frazer, Monica, Swift, Caroline, Gronroos, Noelle N., Sargent, Andrew, Leszko, Michael, Buysman, Erin, Alvarez, Sara, Dunn, Tyler J., Noone, Josh, Guevarra, Mico
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Healthcare 2023
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10567941/
https://www.ncbi.nlm.nih.gov/pubmed/37740832
http://dx.doi.org/10.1007/s12325-023-02677-w

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10567941/
https://www.ncbi.nlm.nih.gov/pubmed/37740832
http://dx.doi.org/10.1007/s12325-023-02677-w

Ejemplares similares